SCHEMBL4339723

SCHEMBL4339723

O=S(=O)(c1cccnc1)n1nnc2ccccc21

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC9A1 P19634 2/20 0.72
CYP2C19 P33261 1/20 0.61
LMNA P02545 1/20 0.52
HPGD P15428 1/20 0.52
HTT P42858 1/20 0.51
ALDH1A1 P00352 1/20 0.50
TSHR P16473 4/20 0.49
KMT2A Q03164 2/20 0.49
HSD17B10 Q99714 2/20 0.49
POLB P06746 1/20 0.48
MEN1 O00255 1/20 0.47
MAPK1 P28482 1/20 0.47
NPSR1 Q6W5P4 2/20 0.46
SMN1; SMN2 Q16637 5/20 0.45
KDM4E B2RXH2 2/20 0.44
GAA P10253 1/20 0.44
NAPRT Q6XQN6 1/20 0.44
CRHBP P24387 1/20 0.42
RECQL P46063 1/20 0.42
CRHR2 Q13324 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29479890 1.00 SLC9A1 (0.72) SLC9A1CYP2C19LMNAHPGDHTT
SCHEMBL2491809 0.84 SLC9A1 (1.00) SLC9A1CYP2C19LMNAHPGDHTT
SCHEMBL29479875 0.84 SLC9A1 (1.00) SLC9A1CYP2C19LMNAHPGDHTT
SCHEMBL2958185 0.83 SLC9A1 (0.97) SLC9A1CYP2C19LMNAHPGDHTT
SCHEMBL19848122 0.82 SLC9A1 (0.54) SLC9A1CYP2C19LMNAHTTALDH1A1
SCHEMBL19911488 0.82 SLC9A1 (0.54) SLC9A1CYP2C19LMNAHTTALDH1A1
SCHEMBL19848386 0.82 SLC9A1 (0.49) SLC9A1CYP2C19KMT2APOLBMEN1
SCHEMBL19911619 0.82 SLC9A1 (0.49) SLC9A1CYP2C19LMNAALDH1A1TSHR
SCHEMBL19848586 0.82 SLC9A1 (0.49) SLC9A1CYP2C19LMNAHPGDHTT
SCHEMBL19848250 0.82 SLC9A1 (0.49) SLC9A1CYP2C19LMNAHPGDHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2014797-A2 Coating composition for interconnection part of electrode and plasma display panel including the same Samsung SDI Co., Ltd. (KR) 2009-01-14 EP claimed
US-20080303439-A1 Coating composition for interconnection part of electrode and plasma display panel including the same SAMSUNG SDI CO., LTD., A CORP. OF THE REPUBLIC OF KOREA (KR) 2008-12-11 US claimed
US-20250007001-A1 LITHIUM SECONDARY BATTERY TERAWATT TECHNOLOGY K.K. (JP) 2025-01-02 US disclosed
US-20240250306-A1 LITHIUM SECONDARY BATTERY TERAWATT TECHNOLOGY K.K. (JP) 2024-07-25 US disclosed
WO-2023170799-A1 LITHIUM SECONDARY BATTERY TeraWatt Technology株式会社 2023-09-14 WO disclosed
US-20230261203-A1 LITHIUM SECONDARY BATTERY TERAWATT TECHNOLOGY K.K. (JP) 2023-08-17 US disclosed
US-20230261203-A1 LITHIUM SECONDARY BATTERY TERAWATT TECHNOLOGY K.K. (JP) 2023-08-17 US disclosed
US-20230261203-A1 LITHIUM SECONDARY BATTERY TERAWATT TECHNOLOGY K.K. (JP) 2023-08-17 US disclosed
WO-2023053295-A1 LITHIUM SECONDARY BATTERY TeraWatt Technology株式会社 2023-04-06 WO disclosed
WO-2022085046-A1 LITHIUM SECONDARY BATTERY TeraWatt Technology株式会社 2022-04-28 WO disclosed
EP-3467930-A1 NONAQUEOUS ELECTROLYTE AND NONAQUEOUS SECONDARY BATTERY ASAHI KASEI KABUSHIKI KAISHA (JP) 2019-04-10 EP disclosed
US-20180062213-A1 Nonaqueous Electrolyte and Nonaqueous Secondary Battery ASAHI KASEI KABUSHIKI KAISHA (JP) 2018-03-01 US disclosed
EP-2014797-A2 Coating composition for interconnection part of electrode and plasma display panel including the same Samsung SDI Co., Ltd. (KR) 2009-01-14 EP disclosed
US-20080303439-A1 Coating composition for interconnection part of electrode and plasma display panel including the same SAMSUNG SDI CO., LTD., A CORP. OF THE REPUBLIC OF KOREA (KR) 2008-12-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180062213-A1 Nonaqueous Electrolyte and Nonaqueous Secondary Battery BPTF, BRD4, KCNN2 SLC9A1 341/4885CYP2C19 1476/4885LMNA 1033/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.